(vianews) - vistin pharma (vistn.ol) is among this list of stock assets with the highest dividend rate and return on equity on the drug manufacturers—specialty & generic industry.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| vistin pharma (vistn.ol) | kr22.90 | 3.13% | 16.03% |
| vetoquinol (veto.pa) | €102.60 | 1.02% | 12.13% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. vistin pharma (vistn.ol)
3.13% forward dividend yield and 16.03% return on equity
vistin pharma asa, through its subsidiary, vistin pharma as, produces and sells active pharmaceutical ingredients (apis) worldwide. it offers metformin hcl apis and direct compressive granulates for the pharmaceutical industry. the company was founded in 1969 and is headquartered in oslo, norway.
earnings per share
as for profitability, vistin pharma has a trailing twelve months eps of kr1.
pe ratio
vistin pharma has a trailing twelve months price to earnings ratio of 22.9. meaning, the purchaser of the share is investing kr22.9 for every norwegian krone of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.03%.
revenue growth
year-on-year quarterly revenue growth grew by 30.8%, now sitting on 438.54m for the twelve trailing months.
sales growth
vistin pharma's sales growth is 10.6% for the ongoing quarter and 6.6% for the next.
dividend yield
as maintained by morningstar, inc., the next dividend payment is on jan 23, 2024, the estimated forward annual dividend rate is 0.75 and the estimated forward annual dividend yield is 3.13%.
more news about vistin pharma.
2. vetoquinol (veto.pa)
1.02% forward dividend yield and 12.13% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 20.64. meaning, the purchaser of the share is investing €20.64 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.13%.
more news about vetoquinol.